InvestorsHub Logo
Post# of 252254
Next 10
Followers 75
Posts 4668
Boards Moderated 0
Alias Born 09/06/2003

Re: acgood post# 137323

Monday, 02/20/2012 2:00:24 AM

Monday, February 20, 2012 2:00:24 AM

Post# of 252254
ISIS - FWIW - Just finished listening to their R&D Day and my initial response is that it was the best biotech R&D Day I've ever seen. (And I have seen 10's). All the science data was relevant and meaningful. Little chest thumping about the size of the market or other items deserving of only a line or two. And the CEO's discussion on balancing the portfolio was absolutely crystal clear and on target.

They even brought up some of the concerns and addressed them head on - e.g. as soon as I saw the CRP target mentioned somewhere early in the presentation I asked of myself the obvious question of whether CRP is a legitimate target or only a marker. And before the end of the presentation the CEO answered head on - yes, it is a risk as to whether it is an actor or just a bystander. But the market is large enough that it is a risk worth taking. A legitimate and considered position. And given their willingness to cancel even successful programs because they look too difficult or they will be a me-too I'd tend to trust them to design a perceptive set of trials and kill it early if appropriate.

PS Do you know what size royalties they typically mean when they say 'double digit'?

PPS Do you know of any background in anti-sense cancer risks? (it is the obvious question when it comes to playing with nucleotides)

PPPS Do you know the kind/size of injection used for their drugs? IM? SC? ...

PPPPS ?How the heck are they planning to make an oral anti-sense?

PPPPPS ?How are they using antisense to fix a splicing problem? (I'd hunt through the patents for this and the previous question - but I do not have the time to filter through 1500 patents so am taking the lazy way out and hoping someone has the answer at hand -g-)

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.